Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.29) by 34.11 percent. This is a 77.86 percent increase over losses of $(3.84) per share from the same period last year.